Product Description
Mechanisms of Action: AURK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nerviano Medical Sciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Multiple Myeloma|Prostate Cancer|T-Cell Peripheral Lymphoma|Chronic Myeloid Leukemia|Pancreatic Cancer|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Breast Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ND | P2 |
Terminated |
Chronic Myeloid Leukemia |
2029-01-23 |
|
| 2012-005157-23 | P2 |
Completed |
T-Cell Peripheral Lymphoma |
2017-11-21 |
|
| 2006-003772-35 | P2 |
Completed |
Ovarian Cancer|Colorectal Cancer|Non-Small-Cell Lung Cancer|Breast Cancer|Pancreatic Cancer |
2012-08-25 |
|
| 2006-006136-21 | P2 |
Completed |
Prostate Cancer |
2011-03-23 |